Day One

• Targeting a tumor suppressor with small molecule glues to reactivate PP2A in cancer
• Mechanistic and structural insights into PP2A holoenzyme stabilization and downstream signaling effects
• Translational potential and development challenges, including chemistry optimization and preclinical efficacy

• Discover how RapaGlues™, a novel class of non-degrading macrocyclic peptide molecular glues, achieve potent, selective target engagement with long residence times, aided by AI/ML-driven design and structural insights
• Learn from case studies using DEL screening and X-ray crystallography that reveal unique binding modes, cryptic pocket engagement, and successful inhibition of challenging targets including transcription factors, SLCs, and TNF-alpha pathway proteins
• Explore strategies to optimize permeability, stability, and oral bioavailability of macrocyclic glues, expanding drug discovery opportunities across diverse and hardto-drug protein classes

• As a promising next-gen proximity-induced therapy, molecular glues have great clinical and commercial value but face serendipitous discovery and technical bottlenecks; XtalPi solves these via a systematic platform combining physics-driven simulation, high-throughput tools and AI-powered VAST™ library, capable of predicting 60B compounds (4B+ synthesizable)
• The company’s technical platform demonstrates proven breakthrough value, capable of tackling challenging targets and achieving efficient optimization of lead compounds with structural support
• XtalPi boasts clear pipeline layout across multiple indications and mature commercial cooperation models, accelerating the translation of molecular glue technology from R&D to clinic and market

Join our speed networking session tailored for Molecular Glue professionals, like yourself, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space.

• Exploring how small molecules such as BI-3802 induce BCL6 polymerization, leading to target sequestration and subsequent proteasomal degradation
• Harnessing chemically controlled on/off oligomerization switches for synthetic biology applications
• BTB-domain polymerization represents a broader mechanism across ZBTB transcription factors, enhancing chromatin occupancy and gene repression

• Explore how chemical switches and molecular glues can reprogram cellular signaling networks beyond traditional protein degradation approaches
• Apply structure-based design strategies to harness chemically induced proximity for overcoming drug resistance and achieving ultra-selective kinase modulation
• Demonstrate how precise modulation of cancer-specific interactomes can open new avenues for therapeutic discovery and innovation

• A screen identified CRBN glues for TBK1
• Structure of the ternary CRBN-glue-TBK1 complex reveals a unique binding mode
• These TBK1 glues are selective over the closely related IKKe kinase

• From serendipity to platforms: Transitioning molecular glues from accidental findings to systematic discovery pipelines with scalable screening and validation strategies
• Beyond degradation: Exploring non-degrading molecular glues that stabilize or reprogram protein-protein interactions to modulate function
• Therapeutic reach: Applying molecular glues across oncology, immunology and neurology to leverage context-specific mechanisms and previously intractable targets

• Mapping the journey from screening to hit identification for a CDK2 molecular glue degrader
• Defining and monitoring critical parameters during lead optimization to ensure biological relevance
• Translating early activity into downstream pharmacology to achieve the desired therapeutic profile

• Dual actions on key pathogenic drivers – simultaneously degrading ZFP91 to suppress inflammation and blocking alpha-synuclein aggregation
• From neuroprotection to functional recovery – demonstrated broad beneficial effects in cognition and motor outcomes
• Validated across multiple models of neurodegeneration – robust and reproducible biological actions confirmed in vitro and in vivo

Take this opportunity to showcase your latest research and innovations with your peers and understand the strategies of your fellow Molecular Glue experts. Visit the website for the full T&Cs of submitting a poster

• Enhancing targeted degradation of amyloid precursor protein (APP) by leveraging CAPRIN1-dependent lysosomal pathways to advance therapeutic strategies for Alzheimer’s disease
• Restoring neuronal stability through selective molecular glue modulation of APP processing, reducing amyloid accumulation and neurotoxicity
• Accelerating translational drug development using AI-assisted ligand and structure-based design to create blood-brain barrier–permeable APP degraders for Alzheimer’s therapy

• VAV1 is an emerging first in class target for a broad range of autoimmune and inflammatory diseases
• Discovery a class of orally available VAV1 degrader with a novel scaffold
• Lead compound demonstrates superior VAV1 degradation activity in vitro and superior efficacy in vivo